Business Development and Growth - The company obtained 17 new trademarks in April 2022, indicating a focus on brand expansion and intellectual property development[4]. - On May 20, 2022, the company was upgraded from the basic layer to the innovation layer of the stock transfer system, reflecting its growth and development[4]. - The company received the acceptance notice from the Beijing Stock Exchange for its public offering and listing application on June 28, 2022, marking a significant step towards capital market access[4]. - The company passed the listing committee's review on December 5, 2022, confirming its compliance with issuance and listing conditions[4]. - The company plans to expand its business scale through the "annual production of 198 tons of Probenecid and other twelve pharmaceutical intermediates project (Phase II)" fundraising project[120]. Financial Performance - The company's operating revenue for 2022 was approximately ¥258.7 million, representing a 23.88% increase from ¥208.8 million in 2021[30]. - The net profit attributable to shareholders for 2022 was approximately ¥56.4 million, a 69.39% increase compared to ¥33.3 million in 2021[30]. - The gross profit margin improved to 37.25% in 2022 from 33.18% in 2021[30]. - Total assets increased by 10.67% to approximately ¥380.7 million in 2022, up from ¥344.0 million in 2021[34]. - Total liabilities decreased by 10.84% to approximately ¥55.9 million in 2022, down from ¥62.7 million in 2021[34]. - The company's net asset attributable to shareholders rose by 18.13% to approximately ¥309.0 million in 2022, compared to ¥261.6 million in 2021[34]. - The cash flow from operating activities for 2022 was approximately ¥57.1 million, a 70.27% increase from ¥33.6 million in 2021[36]. - The accounts receivable turnover rate improved to 9.90 in 2022 from 7.48 in 2021[36]. - The company achieved a revenue of ¥258,700,268.97 in 2022, representing a year-over-year increase of 23.88% compared to ¥208,828,033.83 in 2021[49]. - The net profit attributable to the parent company was ¥56,442,153.33 in 2022, a significant increase of 69.39% from ¥33,321,568.13 in 2021[49]. Risks and Challenges - Sales revenue from the top five customers accounted for 40.05% of total revenue, highlighting a concentration risk in customer dependency[12]. - The company faces risks related to product structure fluctuations, as its main products are specialty raw materials with a diverse range of types[11]. - The company is exposed to environmental protection risks due to stringent regulations in the pharmaceutical industry, which could impact operational costs and compliance[12]. - The company’s profitability may be affected by fluctuations in raw material prices, which are subject to market volatility and inflation[12]. - The company is at risk of intensified market competition as new entrants and existing competitors expand their capacities in the pharmaceutical intermediate and raw material sectors[14]. - The company must adapt to changing regulatory policies in the pharmaceutical industry to maintain compliance and operational effectiveness[15]. - The company faces risks related to continuous product development and technological innovation, which could impact its market position and operational performance if not managed effectively[16]. - The company faces risks related to fluctuations in raw material supply and prices, which can significantly affect profitability[127]. Research and Development - The company plans to enhance its product development and technological innovation capabilities to meet the increasing demands of downstream pharmaceutical manufacturers[16]. - R&D expenses increased by 38.26% to ¥16.63 million, indicating a commitment to innovation and product development[61]. - The company has a strong focus on technological innovation and has obtained multiple certifications, including ISO9001 and GMP for its products[45]. - The company holds 6 invention patents and 19 utility model patents, emphasizing its strong R&D capabilities[53]. - The company has several ongoing R&D projects aimed at optimizing production processes and enhancing product quality, which are expected to improve economic benefits[92]. Environmental and Social Responsibility - The company is actively optimizing production processes to enhance green and clean production, reducing pollutant emissions[53]. - The company has implemented environmental monitoring plans for waste gas, wastewater, and noise, ensuring compliance with national discharge standards[110]. - Wastewater generated by the company is treated to meet the standards of the receiving municipal wastewater treatment plant[111]. - The company has established treatment facilities for various pollutants, ensuring that emissions meet environmental standards[112]. - The company has a comprehensive waste management strategy, ensuring that all waste types are handled in compliance with environmental regulations[112]. - The company has committed to social welfare activities, promoting volunteer spirit and community support during the pandemic[109]. - The company has adhered to the national poverty alleviation policies through various initiatives aimed at supporting vulnerable communities[108]. Shareholder and Governance Commitments - The company has engaged in significant related party transactions, with a total amount of 402,578.88 yuan reported[136]. - The company is currently fulfilling various commitments, including share lock-up and price stabilization commitments[138]. - The actual controller and major shareholders have committed to reducing and regulating related party transactions since January 24, 2014[140]. - The company has outlined penalties for failing to adhere to these commitments, including public explanations and apologies[144]. - The commitments are aimed at ensuring transparency and stability in the company's governance and shareholder relations[140]. - The company has established a three-year shareholder dividend return plan to enhance investor returns and protect the rights of minority shareholders[165]. - The company commits to strict adherence to laws and regulations to improve corporate governance and ensure the protection of shareholder rights[166]. - The company guarantees that the prospectus for the public offering does not contain false statements or omissions, and it will compensate investors for any losses incurred due to such issues[169]. Market Trends and Industry Outlook - The pharmaceutical industry is experiencing rapid global growth driven by population increase, aging society, and enhanced health awareness[115]. - The domestic pharmaceutical industry has significant growth potential, with the market scale expected to expand during the "14th Five-Year Plan" period due to rigid demand[116]. - The global raw material and intermediate industry is benefiting from the steady growth of downstream drug formulation demand, particularly with the expiration of original drug patents[117]. - The company is transitioning from producing low-end bulk raw materials to high-end specialty raw materials, improving product quality and processing capabilities[118]. - The CDMO business is expected to grow rapidly, driven by the need to reduce new drug development costs and improve efficiency[119].

Financial Performance - The company achieved operating revenue of ¥258,700,268.97, an increase of 23.88% compared to the previous year[3] - Net profit attributable to shareholders reached ¥56,442,153.33, up 69.39% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥51,415,806.81, reflecting a 67.82% increase from the previous year[4] - Basic earnings per share increased to ¥1.88, a rise of 69.37% compared to the same period last year[4] Assets and Equity - Total assets at the end of the reporting period were ¥380,716,880.35, a 10.67% increase from the beginning of the period[4] - Shareholders' equity attributable to the company was ¥309,025,777.03, growing by 18.13% from the start of the period[4] - The net asset value per share attributable to shareholders was estimated at ¥10.29, an increase of 18.14% from the beginning of the period[4] Sales Performance - The sales revenue of antiviral, antioxidant, and antithrombotic drug intermediates increased by approximately 58% during the reporting period[5] Cautionary Note - The company emphasizes that the financial data is preliminary and has not been audited, urging investors to be cautious[6] Share Capital - The company maintained a consistent share capital of ¥30,037,500.00 throughout the reporting period[4]

安徽峆一药业股份有限公司 安徽省天长市杨村工业区 安徽峆一药业股份有限公司招股说明书（申报稿） 本公司的发行申请尚未经中国证监会注册。本招股说明书申报稿不具有据以发行股票的法律 效力，投资者应当以正式公告的招股说明书全文作为投资决定的依据。 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证券交易所主 临较大的市场风险。投资者应充分了解北京证券交易所市场的投资风险及本公司所披露的风险因 素，审慎作出投资决定。 保荐机构（主承销商） （安徽省合肥市梅山路 18 号） 联席主承销商 （中国（四川）自由贸易试验区成都市高新区交子大道 177 号中 海国际中心 B 座 17 楼） 1-1-0 证券简称： 峆一药业 证券代码： 430478 要服务创新型中小企业，上市公司具有经营风险高、业绩不稳定、退市风险高等特点，投资者面 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表明其对注册申 请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的盈利能力、 投资价值或者对投资者的收益作出实质性判断或者保证。任何与之相反的声明均属虚假不实 陈述。 根据《证券法》的规定，股票 ...

证券简称： 峆一药业 证券代码： 430478 安徽峆一药业股份有限公司 安徽省天长市杨村工业区 安徽峆一药业股份有限公司招股说明书（申报稿） 本公司的发行申请尚未经中国证监会注册。本招股说明书申报稿不具有据以发行股票的法律 效力，投资者应当以正式公告的招股说明书全文作为投资决定的依据。 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证券交易所主 要服务创新型中小企业，上市公司具有经营风险高、业绩不稳定、退市风险高等特点，投资者面 临较大的市场风险。投资者应充分了解北京证券交易所市场的投资风险及本公司所披露的风险因 素，审慎作出投资决定。 保荐机构（主承销商） （安徽省合肥市梅山路 18 号） 联席主承销商 （中国（四川）自由贸易试验区成都市高新区交子大道 177 号中 1-1-0 海国际中心 B 座 17 楼） 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表明其对注册申 请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的盈利能力、 投资价值或者对投资者的收益作出实质性判断或者保证。任何与之相反的声明均属虚假不实 陈述。 根据《证券法》的规定，股票 ...